Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?

Guinevere Q. Lee, Suzanne McCluskey, Yap Boum, Peter W. Hunt, Jeffrey N. Martin, David Bangsberg, Xiaojiang Gao, Richard R. Harrigan, Jessica E. Haberer, Mark J. Siedner

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Despite a poor toxicity profile, zidovudine supersedes abacavir as an alternative first-line agent in most international treatment-guidelines due to concerns about HLA-B*57:01-related abacavir-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with prior reports, supports the safety of abacavir in the region.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Jun 19 2017

Fingerprint

Africa South of the Sahara
HIV
Uganda
Zidovudine
Hypersensitivity
Guidelines
Safety
abacavir
HLA-B57 antigen

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? / Lee, Guinevere Q.; McCluskey, Suzanne; Boum, Yap; Hunt, Peter W.; Martin, Jeffrey N.; Bangsberg, David; Gao, Xiaojiang; Harrigan, Richard R.; Haberer, Jessica E.; Siedner, Mark J.

In: Journal of Acquired Immune Deficiency Syndromes, 19.06.2017.

Research output: Contribution to journalArticle

Lee, Guinevere Q. ; McCluskey, Suzanne ; Boum, Yap ; Hunt, Peter W. ; Martin, Jeffrey N. ; Bangsberg, David ; Gao, Xiaojiang ; Harrigan, Richard R. ; Haberer, Jessica E. ; Siedner, Mark J. / Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?. In: Journal of Acquired Immune Deficiency Syndromes. 2017.
@article{9fc8f587106449a6b5d9555861678165,
title = "Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?",
abstract = "ABSTRACT: Despite a poor toxicity profile, zidovudine supersedes abacavir as an alternative first-line agent in most international treatment-guidelines due to concerns about HLA-B*57:01-related abacavir-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with prior reports, supports the safety of abacavir in the region.",
author = "Lee, {Guinevere Q.} and Suzanne McCluskey and Yap Boum and Hunt, {Peter W.} and Martin, {Jeffrey N.} and David Bangsberg and Xiaojiang Gao and Harrigan, {Richard R.} and Haberer, {Jessica E.} and Siedner, {Mark J.}",
year = "2017",
month = "6",
day = "19",
doi = "10.1097/QAI.0000000000001487",
language = "English (US)",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?

AU - Lee, Guinevere Q.

AU - McCluskey, Suzanne

AU - Boum, Yap

AU - Hunt, Peter W.

AU - Martin, Jeffrey N.

AU - Bangsberg, David

AU - Gao, Xiaojiang

AU - Harrigan, Richard R.

AU - Haberer, Jessica E.

AU - Siedner, Mark J.

PY - 2017/6/19

Y1 - 2017/6/19

N2 - ABSTRACT: Despite a poor toxicity profile, zidovudine supersedes abacavir as an alternative first-line agent in most international treatment-guidelines due to concerns about HLA-B*57:01-related abacavir-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with prior reports, supports the safety of abacavir in the region.

AB - ABSTRACT: Despite a poor toxicity profile, zidovudine supersedes abacavir as an alternative first-line agent in most international treatment-guidelines due to concerns about HLA-B*57:01-related abacavir-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with prior reports, supports the safety of abacavir in the region.

UR - http://www.scopus.com/inward/record.url?scp=85021134362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021134362&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001487

DO - 10.1097/QAI.0000000000001487

M3 - Article

C2 - 28639996

AN - SCOPUS:85021134362

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

ER -